These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19715908)

  • 21. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients.
    Yeung S; Tsang WK; Tong KL; Wong SH; Lee W; Tang HL; Chan HW; Chan AY
    Transplant Proc; 2004 Sep; 36(7):2084-6. PubMed ID: 15518754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
    Neumayer HH; Budde K; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Clin Nephrol; 1996 May; 45(5):326-31. PubMed ID: 8738665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-year experience with tacrolimus in renal transplantation after late conversion from cyclosporine therapy.
    Videla CO
    Transplant Proc; 2009; 41(6):2659-63. PubMed ID: 19715995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group.
    Transpl Int; 1994; 7 Suppl 1():S247-51. PubMed ID: 11271216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus.
    Lauzurica R; Morales JM; van Hooff J;
    Transpl Int; 2012 Jan; 25(1):48-55. PubMed ID: 21992068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation.
    Kolonko A; Chudek J; Wiecek A
    Transplant Proc; 2011 Oct; 43(8):2950-3. PubMed ID: 21996198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients.
    Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M
    Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
    Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
    Heilman RL; Mazur MJ; Reddy KS; Moss A; Post D; Mulligan D
    Transplant Proc; 2005 May; 37(4):1785-8. PubMed ID: 15919466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful conversion from twice-daily to once-daily tacrolimus in liver transplantation: observational multicenter study.
    Dopazo C; Rodriguez R; Llado L; Calatayud D; Castells L; Ramos E; Molina V; García R; Fabregat J; Charco R
    Clin Transplant; 2012; 26(1):E32-7. PubMed ID: 21958123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure.
    Hougardy JM; Broeders N; Kianda M; Massart A; Madhoun P; Le Moine A; Hoang AD; Mikhalski D; Wissing KM; Abramowicz D
    Transplantation; 2011 Mar; 91(5):566-9. PubMed ID: 21192316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
    Spence MM; Nguyen LM; Hui RL; Chan J
    Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients.
    Umbro I; Tinti F; Mecule A; Bachetoni A; Poli L; Pignatelli A; Alessandri C; Fiacco F; D'Alessandro M; Di Natale V; Berloco PB; Valesini G; Mitterhofer AP
    Transplant Proc; 2012 Sep; 44(7):1907-9. PubMed ID: 22974867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
    Osuna A; Gentil MA; Capdevila L; Cantarell C; Mazuecos A; Pereira P; Rodríguez-Algarra G; González-Molina M;
    Transplant Proc; 2005 Apr; 37(3):1438-40. PubMed ID: 15866630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience.
    Yocum DE; Furst DE; Bensen WG; Burch FX; Borton MA; Mengle-Gaw LJ; Schwartz BD; Wisememandle W; Mekki QA;
    Rheumatology (Oxford); 2004 Aug; 43(8):992-9. PubMed ID: 15014199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.